KPV
KPV (Lys-Pro-Val) is a naturally occurring tripeptide consisting of three amino acids: lysine, proline, and valine. It corresponds to the C-terminal sequence of alpha-melanocyte-stimulating hormone (α-MSH) and has attracted experimental research interest because this small fragment appears to retain some of the parent molecule’s inflammation-modulating properties without reproducing all of α-MSH’s biological activity.
A major focus of KPV research involves inflammatory signaling. Laboratory and preclinical studies have investigated its effects on pathways associated with inflammatory responses, including signaling involving NF-κB and pro-inflammatory cytokines. These mechanisms have made KPV particularly interesting for researchers studying how small peptide fragments may influence cellular inflammatory processes.
KPV has also been investigated extensively within intestinal and epithelial research. Experimental studies using intestinal cells and animal models have examined its relationship with epithelial inflammation, intestinal tissue responses, and transport mechanisms that may allow the peptide to interact with cells of the gastrointestinal tract.
Another area of investigation involves immune-cell signaling. Research has explored how KPV may influence inflammatory responses involving macrophages and other immune-related cells, providing additional insight into the relationship between melanocortin-derived peptides and regulation of inflammatory pathways.
Researchers have additionally investigated KPV in experimental models involving skin and epithelial tissues, reflecting the broader scientific interest in α-MSH-derived peptides and their potential role in regulating localized inflammatory responses.
Importantly, the scientific evidence surrounding KPV remains predominantly preclinical. Findings from cell cultures and animal models should not be interpreted as demonstrating equivalent therapeutic effects in humans. Robust controlled human clinical trials establishing KPV's safety, effectiveness, dosing, or long-term effects are lacking.
KPV is therefore best characterized as an experimental research tripeptide being investigated for inflammatory signaling, immune regulation, and intestinal and epithelial biology, rather than as an established treatment for inflammatory, gastrointestinal, or dermatological conditions.
For laboratory research purposes only. Not for human consumption.
Dalmasso et al., 2008, Gastroenterology: One of the strongest KPV papers for your page. Researchers examined KPV (Lys-Pro-Val), PepT1 transport, NF-κB and MAPK signaling, inflammatory cytokines, intestinal epithelial cells, immune cells, and mouse models of colitis.
Getting et al., 2003, Journal of Pharmacology and Experimental Therapeutics: Examined the C-terminal KPV fragment of α-MSH and its anti-inflammatory activity in experimental models. Interestingly, the researchers found KPV's activity appeared distinct from conventional melanocortin-receptor signaling.
Kannengiesser et al., 2008: Particularly relevant to our intestinal-research section. KPV was studied in two mouse models of intestinal inflammation, with researchers examining inflammatory changes, histology and possible melanocortin-receptor involvement.
Land, 2012: Useful for the epithelial and NF-κB portion of our description. This laboratory study examined KPV in human bronchial epithelial cells, including NF-κB signaling, IL-8, eotaxin and the nuclear transport of p65/RelA.
